Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P. Gaillard V, et al. Among authors: pierard l. Support Care Cancer. 2022 Aug;30(8):6583-6591. doi: 10.1007/s00520-022-07088-1. Epub 2022 Apr 29. Support Care Cancer. 2022. PMID: 35484315
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P. Bischoff H, et al. Among authors: pierard l. Breast Cancer Res Treat. 2023 Feb;198(1):23-29. doi: 10.1007/s10549-022-06844-5. Epub 2022 Dec 23. Breast Cancer Res Treat. 2023. PMID: 36562910
Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas.
Moinard-Butot F, Oriel M, Tricard T, Cazzato RL, Pierard L, Gaillard V, Werle P, Lindner V, Martin S, Schuster C, Roy C, Burgy M, Anthony A, Bigot C, Boudier P, Fritsch A, Olland A, Malouf G, Lang H, Barthélémy P. Moinard-Butot F, et al. Among authors: pierard l. Clin Genitourin Cancer. 2024 Oct;22(5):102134. doi: 10.1016/j.clgc.2024.102134. Epub 2024 Jun 5. Clin Genitourin Cancer. 2024. PMID: 38909529 Free article.
Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérant S, Bartélémy P, Pierard L, Fizazi K, Joly F. Lange M, et al. Among authors: pierard l. BMC Cancer. 2017 Aug 16;17(1):549. doi: 10.1186/s12885-017-3534-8. BMC Cancer. 2017. PMID: 28814281 Free PMC article.
Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak.
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Weindling MK, Fischbach C, Pierard L, Limacher JM, Nader R, Velten M, Petit T. Martin S, et al. Among authors: pierard l. Clin Breast Cancer. 2023 Jan;23(1):32-37. doi: 10.1016/j.clbc.2022.10.006. Epub 2022 Oct 13. Clin Breast Cancer. 2023. PMID: 36414498 Free PMC article.
Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérant S, Bartélémy P, Pierard L, Fizazi K, Joly F. Lange M, et al. Among authors: pierard l. BMC Cancer. 2018 Jan 30;18(1):110. doi: 10.1186/s12885-017-3764-9. BMC Cancer. 2018. PMID: 29382311 Free PMC article.
Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. Insights from the ESC-EORP Valvular Heart Disease II survey.
Dreyfus J, Komar M, Attias D, De Bonis M, Ruschitzka F, Popescu BA, Laroche C, Tribouilloy C, Bogachev Prokophiev A, Mizariene V, Bax JJ, Maggioni AP, Messika-Zeitoun D, Vahanian A, Iung B; EORP VHD II Registry Investigators Group. Dreyfus J, et al. Eur J Heart Fail. 2024 Apr;26(4):994-1003. doi: 10.1002/ejhf.3157. Epub 2024 Feb 19. Eur J Heart Fail. 2024. PMID: 38374610
449 results